Effect of CYP3A inhibition on vesnarinone metabolism in humans

Christoph Wandel, Chim C. Lang, Doug C. Cowart, Armand F. Girard, Steve Bramer, David A. Flockhart, Alastair J. J. Wood

    Research output: Contribution to journalArticle

    13 Citations (Scopus)

    Abstract

    To identify the cytochrome P450 (CYP) enzymes involved in the conversion of vesnarinone to it main primary metabolite OPC-18692 and to investigate the effect of CYP3A inhibition on the pharmacokinetics of vesnarinone in vivo.
    Original languageEnglish
    Pages (from-to)506-511
    Number of pages6
    JournalClinical Pharmacology & Therapeutics
    Volume63
    Issue number5
    DOIs
    Publication statusPublished - 1998
    Event98th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics - Town and Country Hotel, San Diego, California, United States
    Duration: 5 Mar 19978 Mar 1997

    Fingerprint Dive into the research topics of 'Effect of CYP3A inhibition on vesnarinone metabolism in humans'. Together they form a unique fingerprint.

  • Cite this

    Wandel, C., Lang, C. C., Cowart, D. C., Girard, A. F., Bramer, S., Flockhart, D. A., & Wood, A. J. J. (1998). Effect of CYP3A inhibition on vesnarinone metabolism in humans. Clinical Pharmacology & Therapeutics, 63(5), 506-511. https://doi.org/10.1016/S0009-9236(98)90101-1